Intranasal vaccine developer BlueWillow Biologics has announced the appointment of Chad Costley as Chief Medical Officer. Costley, an Atlanta-based primary care physician, has previously served on BlueWillow’s board of directors.
BlueWillow, formerly known as NanoBio, has a number of intranasal vaccines based on its NanoVax technology in preclinical or Phase 1 development, including vaccines against anthrax, influenza, respiratory syncytial virus (RSV), and herpes simplex virus (HSV). In addition, Blue Willow’s pipeline includes several intranasal immunotherapy candidates, and the company recently launched an OTC topical nasal antiseptic called NanoBio Protect.
Costley commented, “The BlueWillow technology platform holds great promise for preventing devastating diseases. The role of CMO includes the responsibility to further advance this exceptional technology and accelerate impactful development. NanoBio Protect is one example of the potential of our unique platform. Along with the entire BlueWillow team, I’m committed to progressing efforts at this critical time. We have an opportunity to make a difference right now, to help protect our communities, and to set the stage for a dramatically improved approach to prevention as the country continues to fight against the spread of infection and takes steps to embrace a return to normalcy.”
BlueWillow CEO David Peralta said, “A wholistic understanding of the population is necessary to effectively develop and efficiently commercialize prevention strategies and treatments. We recently focused our efforts on accelerating the availability of our nasal antiseptic NanoBio Protect to deliver a solution that provides protection against infection during this challenging time. The value Dr. Costley brings to BlueWillow is immeasurable. He has spent decades treating patients. His patient care expertise and business acumen will help guide development efforts in alignment with society’s needs.”
Read the BlueWillow Biologics press release.
